CellBion Co., Ltd. (KOSDAQ:308430)

South Korea flag South Korea · Delayed Price · Currency is KRW
37,700
-250 (-0.66%)
At close: Apr 28, 2026
116.05%
Market Cap 483.75B
Revenue (ttm) 1.95B
Net Income (ttm) -7.57B
Shares Out 12.83M
EPS (ttm) -591.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 76,694
Average Volume 88,804
Open 37,550
Previous Close 37,950
Day's Range 37,450 - 39,200
52-Week Range 14,420 - 42,200
Beta n/a
RSI 66.50
Earnings Date Apr 13, 2026

About CellBion

CellBion Co., Ltd. engages in the research and development of radiopharmaceutical products. Its clinical stage pipeline includes 177Lu-PSMA-DGUL, indicated for prostate cancer radiotherapy, currently under Phase 2 clinical stage; 225Ac-Antibody, indicated for multiple cancer types, currently under pre-clinical stage; 225Ac-DGUL, indicated for prostate cancer radiotherapy, currently under pre-clinical stage; 68Ga-Nota-MSA, indicated for cardiovascular disease diagnosis, currently under Phase 2 clinical stage; 99mTc-MSA-ICG, indicated for lymphos... [Read more]

Industry Pharmaceutical Preparations
Founded 2010
Employees 55
Stock Exchange KOSDAQ
Ticker Symbol 308430
Full Company Profile

Financial Performance

In 2025, CellBion's revenue was 1.95 billion, a decrease of -15.05% compared to the previous year's 2.29 billion. Losses were -7.57 billion, 4.23% more than in 2024.

Financial Statements

News

There is no news available yet.